Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

The Joint Defense Privilege and Selective Waiver in Government Investigations

Related Content

Southern District of New York Allows Certain Investor Claims Against UiPath to Survive Dismissal

SEC Outlook: Potential Updates Under Nominated Chairman Atkins

Northern District of California Partially Dismisses Investor Suit Against Meta, but Claims Survive Challenging Statements About Consistent Application of Community Standards and Effect of Instagram on Youth

Delaware Chancery Court Grants Software Company’s Motion to Dismiss Stockholder Class Action Lawsuit After Stockholder Vote Cleansed Alleged Improprieties in Connection with Merger

U.S. Supreme Court Significantly Curtails SEC Enforcement Forum Discretion

Northern District of California Grants SEC Motion to Enforce Subpoena Compelling Testimony of Elon Musk

Courts Address Obligations (or Not) to Disclose Back and Forth with FDA. Read more about it and other key decisions in this edition.

Securities Snapshot: Court Confirms that Dilution of Shareholders May Constitute Both a Direct and Derivative Harm

2024-2025 Key Trends and Updates: Securities Litigation Against Life Sciences Companies

Best Lawyers Best Law Firms 2025 Names Goodwin Biotechnology and Life Sciences Law Firm of the Year for the Eighth Time and Recognizes 55 Practice Areas

Benchmark Litigation US 2025 Recognizes 45 Goodwin Litigators

The Future of Non-Compete Agreements in America

Antitrust Implications of State Regulators’ Increasing Scrutiny

The Legal 500 US 2024 Recognizes 44 Goodwin Practices and 186 Lawyers

Chambers USA 2024 Recognizes Goodwin Practices and Lawyers for Exceptional Client Service

ACI's 19th FCPA & Anti-Corruption for the Life Sciences Industry

Securities Litigation & SEC Enforcement